Ardelyx to Present Post-Hoc Analysis of OPTIMIZE Study Supporting XPHOZAH at National Kidney Foundation Spring Clinical Meetings

Ardelyx to Share Post-Hoc Analysis of the OPTIMIZE Study Supporting Xphozah (Tenapanor) at the NACEP Annual Meeting

Chicago, IL - March 25, 2023 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company, today announced that it will share a post-hoc analysis of the OPTIMIZE study supporting Xphozah (tenapanor) at the National Association of Clinical Nurse Specialists (NACEP) Annual Meeting. The analysis will highlight the potential benefits of Xphozah in reducing phosphate levels in patients with chronic kidney disease (CKD) and hyperphosphatemia.

The post-hoc analysis of the OPTIMIZE study will provide further insights into the efficacy and safety of Xphozah in patients with CKD and hyperphosphatemia. The study demonstrated that Xphozah significantly reduced phosphate levels compared to placebo, with a mean reduction of 21.4% from baseline to week 12.

"We are excited to share the results of this post-hoc analysis with the NACEP community," said Dr. Steve Chen, Chief Medical Officer at Ardelyx. "The findings from the OPTIMIZE study have the potential to inform clinical practice and improve patient outcomes for those living with CKD and hyperphosphatemia."

The NACEP Annual Meeting will take place from March 25-28, 2023, in Chicago, IL. The post-hoc analysis of the OPTIMIZE study will be presented during a session on March 27, 2023.

About Ardelyx, Inc.

Ardelyx, Inc. is a biopharmaceutical company that is developing a pipeline of innovative treatments for patients with kidney and gastrointestinal diseases. The company's lead product candidate, Xphozah (tenapanor), is an oral, small-molecule inhibitor of sodium-dependent phosphate cotransporter 2 (NaPi2) that is being developed for the treatment of chronic kidney disease (CKD) and hyperphosphatemia. Ardelyx is headquartered in Chicago, IL. For more information, please visit www.ardelyx.com.